DOCSLIB.ORG

有限公司 API Antibiotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
有限公司 API Antibiotics ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com API Antibiotics Product Code CAS Product Name PH-5919C 69401-50-9 14-HYDROXYCARMINOMYCIN PH-2643B 14-HYDROXYCLARITHROMYCIN METABOLITE PH-3247A 19130-96-2 1-DEOXYNOJIRIMYCIN 70956-02-4 PH-3247B 73285-50-4 1-DEOXYNOJIRIMYCIN HYDROCHLORIDE PH-1143CA 280578-49-6 21-AMINOEPOTHILONE B PH-0156C 4708-96-7 7-MONODEMETHYL MINOCYCLINE PH-0156BA 149934-21-4 9-AMINOMINOCYCLINE HYDROCHLORIDE PH-0156BC 149934-20-3 9-AMINOMINOCYCLINE SULFATE PH-1642B ACETYLMIDECAMYCIN PH-1979B 24916-51-6 ACETYLSPIRAMYCIN PH-1743A 57576-44-0 ACLARUBICIN PH-1743B 75443-99-1 ACLARUBICIN HYDROCHLORIDE PH-3456 50-76-0 ACTINOMYCIN D PH-5781A 1162-65-8 AFLATOXIN B1 PH-5781B 7220-81-7 AFLATOXIN B2 Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 27 Product Code CAS Product Name PH-5781C 1165-39-5 AFLATOXIN G1 PH-5781D 7241-98-7 AFLATOXIN G2 PH-5781E 6795-23-9 AFLATOXIN M1 PH-2277 1414-39-7 ALBOMYCIN PH-3177AD 73807-55-3 ALLITIN PH-1420 37517-28-5 AMIKACIN DIHYDRATE PH-1994 AMIKACIN DISULFATE PH-1418 39831-55-5 AMIKACIN SULFATE PH-1932B 34642-77-8 AMOXYCILLIN SODIUM PH-1932A 61336-70-7 AMOXYCILLIN TRIHYDRATE 26787-78-0 (BASE) PH-1433 1397-89-3 AMPHOTERICIN B PH-1720A 69-53-4 AMPICILLIN ANHYDROUS PH-1720C 69-52-3 AMPICILLIN SODIUM PH-1720D AMPICILLIN SODIUM + CLOXACILLIN SODIUM (1:1) PH-1720B 7177-48-2 AMPICILLIN TRIHYDRATE PH-0064 161814-49-9 AMPRENAVIR PH-1957C 9032-08-0 AMYLOGLUCOSIDASE PH-0382CA 166663-25-8 ANIDULAFUNGIN PH-1422AA 66584-72-3 ANSAMITOCIN P-3 PH-1422AB 66547-09-9 ANSAMITOCIN P-3' PH-4609A 37321-09-8 APRAMYCIN PH-4609B 41194-16-5 APRAMYCIN SULPHATE PH-2853A 51025-85-5 ARBEKACIN ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 2 of 27 Product Code CAS Product Name PH-3164A 63358-49-6 ASPOXICILLIN PH-5438A 55779-06-1 ASTROMICIN PH-4490B 134523-03-8 ATORVASTATIN CALCIUM PH-2045AK 65195-55-3 AVERMECTIN B1A PH-2045AQ 65195-56-4 AVERMECTIN B1B PH-1432A 11051-71-1 AVILAMYCIN PH-0306 13838-08-9 AZIDAMFENICOL PH-3022A 83905-01-5 AZITHROMYCIN PH-3022B 117772-70-0 AZITHROMYCIN DIHYDRATE PH-3022C 121470-24-4 AZITHROMYCIN MONOHYDRATE PH-2382A 37091-66-0 AZLOCILLIN PH-2382B 37091-65-9 AZLOCILLIN SODIUM PH-3322 27548-93-2 BACCATIN III PH-1445A 1405-87-4 BACITRACIN PH-1445C 55852-84-1 BACITRACIN METHYLENE DISALICYLATE PH-1445B 1405-89-6 BACITRACIN ZINC PH-0179CA 4696-76-8 BEKANAMYCIN PH-0179CB 29701-07-3 BEKANAMYCIN SULFATE PH-0245AA 65-85-0 BENZOIC ACID PH-0104F 41372-02-5 BENZYLPENICILLIN BENZATHINE PH-0104FB 1538-09-6 BENZYLPENICILLIN BENZATHINE TETRAHYDRATE PH-5537 120410-24-4 BIAPENEM 155835-09-9 PH-1460A 11056-06-7 BLEOMYCIN 9041-93-4 (SULFATE) ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 3 of 27 Product Code CAS Product Name PH-1460C 11116-31-7 BLEOMYCIN A2 PH-1460B 11116-32-8 BLEOMYCIN A5 PH-1460BB 55658-47-4 BLEOMYCIN A5 HYDROCHLORIDE PH-1460F BLEOMYCIN A6 PH-1460G 9060-10-0 BLEOMYCIN B2 PH-1460GB BLEOMYCIN B2 TRIHYDROCHLORIDE PH-1460D 67763-87-5 BLEOMYCIN HYDROCHLORIDE PH-1460E 9041-93-4 BLEOMYCIN SULFATE PH-0123 28889-87-4 BLP 1654 37762-64-4 (SODIUM SALT) PH-5038BA 134-95-2 CALCIUM MANDELATE PH-1468B 1405-37-4 CAPASTAT SULFATE PH-1468A 11003-38-6 CAPREOMYCIN PH-0134A 4697-36-3 CARBENICILLIN PH-0134B 4800-94-6 CARBENICILLIN SODIUM PH-5919A 50935-04-1 CARUBICIN 39472-31-6 PH-5919B 52794-97-5 CARUBICIN HYDROCHLORIDE PH-1251A 87638-04-8 CARUMONAM 86832-68-0 (DISODIUM) PH-0382BA 162808-62-0 CASPOFUNGIN 179463-17-3 (DIACETATE) PH-0149 23239-41-0 CEFACETRILE SODIUM 10206-21-0 (BASE) PH-2146 53994-73-3 CEFACLOR ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 4 of 27 Product Code CAS Product Name PH-2092 50370-12-2 CEFADROXIL 66592-87-8 (MONOHYDRATE) PH-5342 5575-21-3 CEFALONIUM PH-2238 34444-01-4 CEFAMANDOLE PH-2238C 58648-57-0 CEFAMANDOLE LITHIUM PH-2238B 42540-40-9 CEFAMANDOLE NAFATE PH-4474 CEFATAXIME SODIUM PH-5594 33075-00-2 CEFATHIAMIDINE PH-1668A 51627-14-6 CEFATRIZINE PH-1668B 64217-62-5 CEFATRIZINE PROPYLENE GLYCOL PH-4893A 56187-47-4 CEFAZEDONE PH-4893B 63521-15-3 CEFAZEDONE SODIUM PH-1473A 25953-19-9 CEFAZOLIN PH-1473B 27164-46-1 CEFAZOLIN SODIUM PH-2047DA 76610-84-9 CEFBUPERAZONE PH-2047DC 76648-01-6 CEFBUPERAZONE SODIUM PH-0146AA 135889-00-8 CEFCAPENE PH-0146AE 105889-45-0 CEFCAPENE PIVOXIL PH-0146AG 147816-23-7 CEFCAPENE PIVOXIL HYDROCHLORIDE PH-0146AK 147816-24-8 CEFCAPENE PIVOXIL HYDROCHLORIDE MONOHYDRATE PH-4956 91832-40-5 CEFDINIR PH-5205B 104145-95-1 CEFDITOREN PH-5205 117467-28-4 CEFDITOREN PIVOXIL PH-5205C 104146-53-4 CEFDITOREN SODIUM ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 5 of 27 Product Code CAS Product Name PH-5110AA 88040-23-7 CEFEPIME PH-5110BC 88040-23-7 + 74-79-3 CEFEPIME + L-ARGININE 143892-90-4 PH-5110BA 107648-80-6 + 74-79-3 CEFEPIME HYDROCHLORIDE + L-ARGININE 143892-90-4 PH-5110AC 107648-80-6 CEFEPIME HYDROCHLORIDE ANHYDROUS PH-5110AB 123171-59-5 CEFEPIME HYDROCHLORIDE MONOHYDRATE PH-5110AD CEFEPIME SODIUM PH-5110AE 107648-78-2 CEFEPIME SULFATE PH-4088C 65243-33-6 CEFERAMET PIVOXYL PH-4088A 65052-63-3 CEFETAMET PH-4088B 111696-23-2 CEFETAMET PIVOXIL HYDROCHLORIDE PH-3501 79350-37-1 CEFIXIME PH-2235A 56796-20-4 CEFMETAZOLE PH-2235B 56796-39-5 CEFMETAZOLE SODIUM PH-5748A 75481-73-1 CEFMINOX 84305-41-9 PH-5748B 75498-96-3 CEFMINOX SODIUM PH-4996A 69739-16-8 CEFODIZIME PH-4996B 86329-79-5 CEFODIZIME SODIUM PH-1234A 61270-58-4 CEFONICID PH-1234B 61270-78-8 CEFONICID DISODIUM PH-1234C 71420-79-6 CEFONICID MONOSODIUM PH-2047AA 62893-19-0 CEFOPERAZONE 113826-44-1 (DIHYDRATE) ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 6 of 27 Product Code CAS Product Name PH-2047AC 62893-20-3 CEFOPERAZONE SODIUM PH-2047CA CEFOPERAZONE SODIUM + SULBACTAM SODIUM (1:1) PH-2047CB CEFOPERAZONE SODIUM + SULBACTAM SODIUM (2:1) PH-5584B 122841-10-5 CEFOSELIS PH-5584A 122841-12-7 CEFOSELIS SULFATE PH-1830AA 63527-52-6 CEFOTAXIME PH-1830AB 64485-93-4 CEFOTAXIME SODIUM PH-5615A 69712-56-7 CEFOTETAN PH-5615C 74356-00-6 CEFOTETAN DISODIUM PH-2234B 61622-34-2 CEFOTIAM PH-2234A 66309-69-1 CEFOTIAM HYDROCHLORIDE PH-2101B 35607-66-0 CEFOXITIN PH-2101 33564-30-6 CEFOXITIN SODIUM PH-5563 113359-04-9 CEFOZOPRAN PH-0147AA 70797-11-4 CEFPIRAMIDE PH-0147AE 74849-93-7 CEFPIRAMIDE SODIUM PH-4955AA 84957-29-9 CEFPIROME PH-4955CA CEFPIROME DIHYDROIODIDE PH-4955BA 98753-19-6 CEFPIROME SULFATE PH-4955BE 98753-19-6 CEFPIROME SULFATE (BUFFERED WITH SODIUM CARBONATE) PH-4558A 80210-62-4 CEFPODOXIME PH-4558B 87239-81-4 CEFPODOXIME PROXETIL PH-4558C 82619-04-3 CEFPODOXIME SODIUM PH-0065A 92665-29-7 CEFPROZIL ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 7 of 27 Product Code CAS Product Name PH-0065B 121123-17-9 CEFPROZIL MONOHYDRATE PH-5785A 84957-30-2 CEFQUINOME PH-5785B 118443-89-3 CEFQUINOME SULFATE 123766-80-3 (FORMERLY) PH-4085 CEFRADINE + L-ARGININE PH-5365 52152-93-9 CEFSULODIN SODIUM PH-2529AA 189345-04-8 CEFTAROLINE PH-2529BA 229016-73-3 CEFTAROLINE FOSAMIL PH-2529EC 400827-44-3 CEFTAROLINE FOSAMIL COMPOUND WITH ACETONITRILE (1:1) PH-2529EA 400827-53-4 CEFTAROLINE FOSAMIL COMPOUND WITH ACETONITRILE (1:1) MONOHYDRATE PH-2529BC 400827-79-4 CEFTAROLINE FOSAMIL DISODIUM SALT PH-2529CC 595568-96-0 CEFTAROLINE FOSAMIL MONOACETATE PH-2529CA 400827-55-6 CEFTAROLINE FOSAMIL MONOACETATE MONOHYDRATE 866021-48-9 PH-2529DA 400827-56-7 CEFTAROLINE FOSAMIL MONOPROPANOATE MONOHYDRATE PH-2529DC 400827-48-7 CEFTAROLINE FOSAMIL PROPANOATE PH-3659A 72558-82-8 CEFTAZIDIME PH-3659C CEFTAZIDIME + SODIUM CARBONATE PH-3659E 73547-70-3 CEFTAZIDIME DIHYDROCHLORIDE PH-3659F 80904-83-2 CEFTAZIDIME MONOBACTAM PH-3659D 78439-06-2 CEFTAZIDIME PENTAHYDRATE PH-3659B CEFTAZIDIME SODIUM PH-1666AA 26973-24-0 CEFTEZOLE PH-1666CA CEFTEZOLE IMPURITY 2 (REFERENCE GRADE) PH-1666AE 41136-22-5 CEFTEZOLE SODIUM ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Site: http://www.yickvic.com : E-mail: [email protected] : Tel: (852) 25412772 : Fax: (852) 2523444 Page 8 of 27 Product Code CAS Product Name PH-0148AA 97519-39-6 CEFTIBUTEN PH-4830A 80370-57-6 CEFTIOFUR PH-4830C 103980-44-5 CEFTIOFUR HYDROCHLORIDE PH-4830B 104010-37-9 CEFTIOFUR SODIUM PH-1830AD 69132-42-9 CEFTIOXIDE 71048-88-9 PH-4734B 68401-81-0 CEFTIZOXIME PH-4734 68401-82-1 CEFTIZOXIME SODIUM PH-2009A 73384-59-5 CEFTRIAXONE PH-2009B 104376-79-6 CEFTRIAXONE SODIUM,HEMI(HEPTAHYDRATE) 74578-69-1 (ANHYDROUS) PH-3147A 55268-75-2 CEFUROXIME PH-3147C 64544-07-6 CEFUROXIME AXETIL PH-3147B 56238-63-2 CEFUROXIME SODIUM PH-0144AA 15686-71-2 CEPHALEXIN PH-0144CA 53950-14-4 CEPHALEXIN LYSINATE PH-0144AC 23325-78-2 CEPHALEXIN MONOHYDRATE PH-0144BA 38932-40-0 CEPHALEXIN SODIUM PH-0143 3577-01-3 CEPHALOGLYCIN PH-0142 50-59-9 CEPHALORIDINE PH-0139A 153-61-7 CEPHALOTHIN PH-0139B 58-71-9 CEPHALOTHIN SODIUM PH-2115 38821-53-3 CEPHRADINE PH-0261AA 8044-71-1 CETRIMIDE 505-86-2 (HYDROXIDE) ® Copyright © 2017 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD.
Load more

Recommended publications
  • Redalyc.Patterns of Antimicrobial Therapy in Acute Tonsillitis: a Cross
    Anais da Academia Brasileira de Ciências ISSN: 0001-3765 [email protected] Academia Brasileira de Ciências Brasil JOHN, LISHA J.; CHERIAN, MEENU; SREEDHARAN, JAYADEVAN; CHERIAN, TAMBI Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE Anais da Academia Brasileira de Ciências, vol. 86, núm. 1, enero-marzo, 2014, pp. 451-457 Academia Brasileira de Ciências Rio de Janeiro, Brasil Available in: http://www.redalyc.org/articulo.oa?id=32730090032 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Anais da Academia Brasileira de Ciências (2014) 86(1): 451-457 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201420120036 www.scielo.br/aabc Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE LISHA J. JOHN1, MEENU CHERIAN2, JAYADEVAN SREEDHARAN3 and TAMBI CHERIAN2 1Department of Pharmacology, Gulf Medical University, 4184, Ajman, United Arab Emirates 2Department of ENT, Gulf Medical College Hospital, 4184, Ajman, United Arab Emirates 3Statistical Support Facility, Centre for Advanced Biomedical Research and Innovation, Gulf Medical University, 4184, Ajman, United Arab Emirates Manuscript received on December 20, 2012; accepted for publication on October 14, 2013 ABSTRACT Background: Diseases of the ear, nose and throat (ENT) are associated with significant impairment of the daily life and a major cause for absenteeism from work.
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • 595 PART 441—PENEM ANTIBIOTIC DRUGS Subpart A—Bulk Drugs
    Food and Drug Administration, HHS § 441.20a (6) pH. Proceed as directed in § 436.202 imipenem per milliliter at 25 °C is ¶85° of this chapter, using an aqueous solu- to ¶95° on an anhydrous basis. tion containing 60 milligrams per mil- (vi) It gives a positive identity test. liliter. (vii) It is crystalline. (7) Penicillin G content. Proceed as di- (2) Labeling. It shall be labeled in ac- rected in § 436.316 of this chapter. cordance with the requirements of (8) Crystallinity. Proceed as directed § 432.5 of this chapter. in § 436.203(a) of this chapter. (3) Requests for certification; samples. (9) Heat stability. Proceed as directed In addition to complying with the re- in § 436.214 of this chapter. quirements of § 431.1 of this chapter, [42 FR 59873, Nov. 22, 1977; 43 FR 2393, Jan. 17, each such request shall contain: 1978, as amended at 45 FR 22922, Apr. 4, 1980; (i) Results of tests and assays on the 50 FR 19918, 19919, May 13, 1985] batch for potency, sterility, pyrogens, loss on drying, specific rotation, iden- PART 441ÐPENEM ANTIBIOTIC tity, and crystallinity. DRUGS (ii) Samples, if required by the Direc- tor, Center for Drug Evaluation and Subpart AÐBulk Drugs Research: (a) For all tests except sterility: 10 Sec. 441.20a Sterile imipenem monohydrate. packages, each containing approxi- mately 500 milligrams. Subpart BÐ[Reserved] (b) For sterility testing: 20 packages, each containing equal portions of ap- Subpart CÐInjectable Dosage Forms proximately 300 milligrams. 441.220 Imipenem monohydrate-cilastatin (b) Tests and methods of assayÐ(1) Po- sodium injectable dosage forms.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Summary of Product Characteristics
    Revised: March 2021 AN: 01885/2020 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cepravin Dry Cow 250mg Intramammary suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Constituent: per syringe Cefalonium 0.250 g (as cefalonium dihydrate) For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Intramammary suspension 4. CLINICAL PARTICULARS 4.1 Target species Cattle 4.2 Indications for use, specifying the target species Recommended for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period. 4.3 Contraindications Not for use in the lactating cow. Not intended for use within 54 days of calving. 4.4 Special Warnings: No special warnings are considered necessary. 4.5 Special precautions for use i. Special precautions for use in animals Use of the product should be based on susceptibility testing of the bacteria isolated from milk samples from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Page 1 of 8 Revised: March 2021 AN: 01885/2020 Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalonium and may decrease the effectiveness of treatment with other beta lactams. Dry cow therapy protocols should take local and national policies on antimicrobial use into consideration, and undergo regular veterinary review. The feeding to calves of milk containing residues of cefalonium that could select for antimicrobial-resistant bacteria (e.g. production of beta-lactamases) should be avoided up to the end of the milk withdrawal period, except during the colostral phase.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Urological Infections
    Guidelines on Urological Infections M. Grabe (chair), R. Bartoletti, T.E. Bjerklund-Johansen, H.M. Çek, R.S. Pickard, P. Tenke, F. Wagenlehner, B. Wullt © European Association of Urology 2014 TABLE OF CONTENTS PAGE 1. INTRODUCTION 8 1.1 Background 8 1.2 Bacterial resistance development 8 1.3 The aim of the guidelines 8 1.4 Pathogenesis of UTIs 8 1.5 Microbiological and other laboratory findings 9 1.6 Methodology 10 1.6.1 Level of evidence and grade of guideline recommendations 10 1.6.2 Publication history 10 1.7 References 11 2. CLASSIFICATION OF UTIs 12 2.1 Introduction 12 2.2 Anatomical level of infection 12 2.3 Grade of severity 13 2.4 Pathogens 14 2.5 Classification of UTI 14 2.6 Reference 15 3. UNCOMPLICATED UTIS IN ADULTS 15 3.1 Summary and recommendations 15 3.2 Definition 15 3.2.1 Aetiological spectrum 15 3.3 Acute uncomplicated sporadic cystitis in premenopausal, non-pregnant women 15 3.3.1 Diagnosis 15 3.3.1.1 Clinical diagnosis 15 3.3.1.2 Laboratory diagnosis 15 3.3.2 Therapy 15 3.3.3 Follow-up 16 3.4 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 16 3.4.1 Diagnosis 16 3.4.1.1 Clinical diagnosis 16 3.4.1.2 Laboratory diagnosis 16 3.4.1.3 Imaging diagnosis 16 3.4.2 Therapy 17 3.4.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 17 3.4.2.2 Severe cases of acute uncomplicated pyelonephritis 17 3.4.3 Follow-up 19 3.5 Recurrent uncomplicated UTIs in premenopausal women 20 3.5.1 Diagnosis 20 3.5.2 Antimicrobial treatment and prevention 20 3.5.2.1 Antimicrobial prophylaxis 20 3.5.3 Non-antimicrobial
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]